Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Wahed FTSE USA Shariah ETF (HLAL) vs UnitedHealth Group Inc (UNH) Price & Performance

Wahed FTSE USA Shariah ETFTrade
UnitedHealth Group IncTrade

Price performance (Past 24H)

Key statistics

Wahed FTSE USA Shariah ETF vs UnitedHealth Group Inc — how do they compare? Wahed FTSE USA Shariah ETF trades at $75.91 (market cap $1.00B), while UnitedHealth Group Inc trades at $379.3 (market cap $332.96B). The key difference: UnitedHealth Group Inc is far larger — about 333× Wahed FTSE USA Shariah ETF's market cap, and UnitedHealth Group Inc pays a 2.5% dividend while Wahed FTSE USA Shariah ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Wahed FTSE USA Shariah ETF for 66 Days and UnitedHealth Group Inc for 97 Days on average.

HLALUNH
Market Cap
$1.00B$332.96B
Volume
51,1377,273,749
Sector
Sector/ThematicHealth
52-Week High
$76.54$436.35
52-Week Low
$57.46$259.02
Typical Hold Time
66 Days97 Days
Enterprise Value
—$374.82B
Dividend Yield
—2.5%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Wahed FTSE USA Shariah ETF

HLAL trades at $75.91, down 0.69% today, with a bullish technical signal from moving averages but bearish oscillators. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. A dividend of $0.10 is scheduled for September 2026, indicating a long-term income component. The stock shows mixed signals with strong moving average support but overbought RSI levels.

The outlook is cautiously optimistic due to bullish moving averages, but high RSI suggests near-term pullback risk. Investment opportunity lies in technical strength, while risks include lack of recent fundamental data and potential volatility from overbought conditions. Investors should await updated financials for a clearer picture.

UnitedHealth Group Inc

UnitedHealth Group (UNH) trades at $370.95, down 1.34% on the day, amid a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $6.38 versus $4.91 expected, and raised full-year guidance. Revenue for 2025 reached $447.57 billion, though net income margin declined to 2.69%. Analyst consensus remains strongly bullish with an 82.69% buy rating and a $470.11 price target, suggesting significant upside from current levels.

UNH presents a compelling investment case driven by earnings beats, raised 2026 outlook, and strategic initiatives like AI investment in Optum. Key risks include regulatory pressures in healthcare, volatility from Medicare Advantage plan changes, and margin compression. The stock's valuation at a P/E of 23.84 appears reasonable given growth prospects, but investors should weigh execution risks against the positive analyst sentiment and institutional backing.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HLAL
97% Buy3% Sell
Avg holding period · 66 Days
UNH
71% Buy29% Sell
Avg holding period · 97 Days

Top news

Latest headlines on both assets

About Wahed FTSE USA Shariah ETF

HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.

Read more on HLAL →

About UnitedHealth Group Inc

UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.

Read more on UNH →